Utama › Kanser Ginjal › New York › New York City
Kajian klinikal Kanser Ginjal di New York City, NY
15 kajian untuk Kanser Ginjal sedang mencari peserta di lokasi dalam dan sekitar New York City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Mengambil pesertaFasa 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- NEO-811 NYC Site, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 3
- Research Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
- NYU Langone Medical Center, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Mengambil pesertaFasa 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- dan 1 lagi
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Mengambil pesertaFasa 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Mengambil peserta
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Mengambil pesertaFasa 1
- Columbia University Irving Medical Center, New York
Kidney Cancer DNA Registry
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Memorial Sloan Kettering Cancer Center, New York
Decision Aid (DA) for Renal Patients
Mengambil peserta
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- NYU Langone Health, New York
Kajian Kanser Ginjal di bandar lain
- Boston, MA12 kajian
- Nashville, TN12 kajian
- Houston, TX10 kajian
- San Diego, CA9 kajian
- St. Louis, MO9 kajian
- Dallas, TX9 kajian
- Washington, DC9 kajian
- Seattle, WA8 kajian
- Edison, NJ8 kajian
- Miami, FL8 kajian
- Los Angeles, CA7 kajian
- Rochester, MN7 kajian
Kajian lain di New York City
- Kanser Payudara136 kajian
- Kanser Paru-paru Bukan Sel Kecil121 kajian
- Kanser (semua jenis)109 kajian
- Kanser Prostat103 kajian
- Kanser Metastatik93 kajian
- Kanser Kolorektal78 kajian
- Kanser Ovari69 kajian
- Kanser Paru-paru60 kajian
- Mieloma Pelbagai60 kajian
- Kanser Pankreas60 kajian
- Kanser Endometrium52 kajian
- Leukemia Mieloid Akut51 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.